The options paper suggested a capped special funding program separate from the PBS or a legislative change to enable conditional listings on the PBS. The special funding program would be more straightforward and timely. …
A simple, timely option for a 'bridging fund' that can fit within the existing legal framework
July 10, 2024 Latest NewsBioPharmaComment
Latest Video
New Stories
-
Syntara receives FDA guidance for amsulostat in myelofibrosis treatment
August 11, 2025 - - Australian Biotech -
Noxopharm advances HERACLES trial for novel autoimmune disease drug
August 11, 2025 - - Australian Biotech -
Could the realities of AI quickly date or even swamp the HTA Review outcomes?
August 11, 2025 - - Latest News -
We asked ChatGPT to produce a podcast script explaining the pros and cons of the HTA Review
August 10, 2025 - - Latest News -
PYC Therapeutics accelerates clinical progress of PYC-003 in PKD trial
August 10, 2025 - - Australian Biotech -
Neuren expands NNZ-2591 pipeline to include SYNGAP1-related disorder
August 10, 2025 - - Australian Biotech -
AI has to be seen as a generational opportunity to get medicines to patients faster
August 10, 2025 - - Latest News